The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Relationship between undetectable PSA nadir and outcomes for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in IRONMAN, the International Registry for Men with Advanced Prostate Cancer.
 
Hannah McManus
Consulting or Advisory Role - Pfizer/Astellas
 
Lauren Howard
No Relationships to Disclose
 
Kerri-Anne Crowell
No Relationships to Disclose
 
Terry Hyslop
Research Funding - Pfizer
 
Karen Autio
Research Funding - Amgen (Inst); AstraZeneca (Inst); Janssen (Inst); Lilly (Inst); Pfizer (Inst); Tizona Therapeutics, Inc. (Inst)
 
Dana Rathkopf
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb/Celgene; Genentech; Janssen; Myovant Sciences; Novartis; Promontory
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb/Celgene (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Novartis (Inst); Promontory Therapeutics (Inst)
 
Robert Dreicer
Consulting or Advisory Role - Astellas Pharma; AVEO; Bayer; Gilead Sciences; Janssen Oncology; Macrogenics; Merck; Pfizer
Research Funding - Arvinas (Inst); Exelixis (Inst); Seagen (Inst)
 
Kim Chi
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; BMS GmbH & Co. KG; BMS GmbH & Co. KG; Janssen; Merck; Novartis; Pfizer; POINT Biopharma; Roche
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; POINT Biopharma; Roche
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); ESSA (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
 
Michael Ong
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Janssen; Merck; Novartis / AAA; Pfizer
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Janssen; Merck; Pfizer/EMD Serono; Sanofi
Research Funding - AstraZeneca (Inst); BMS (Inst)
Travel, Accommodations, Expenses - Janssen
 
Joaquin Mateo
Consulting or Advisory Role - Amunix; AstraZeneca; Daiichi Sankyo Europe GmbH; Illumina; MSD; Nuage Therapeutics; Pfizer
Speakers' Bureau - AstraZeneca; Guardant Health; Janssen; Pfizer
Research Funding - Amgen (Inst); AstraZeneca (Inst); Pfizer (Inst)
Other Relationship - Nuage Therapeutics
 
Deborah Enting
Speakers' Bureau - Ipsen; Janssen Oncology; Merck; Pfizer
Travel, Accommodations, Expenses - MSD
 
Emilio Esteban
Travel, Accommodations, Expenses - Pfizer/EMD Serono; Pfizer/EMD Serono
 
Vincent Khoo
No Relationships to Disclose
 
Amanda McMannis
No Relationships to Disclose
 
Rebecca Green
Employment - PCCTC
Stock and Other Ownership Interests - Opollo Technologies (I)
Research Funding - PCCTC (Inst)
 
Shannon Pileggi
No Relationships to Disclose
 
Jake Vinson
No Relationships to Disclose
 
Philip Kantoff
Employment - Convergent Therapeutics
Leadership - Context Therapeutics; Convergent Therapeutics; ESSA
Stock and Other Ownership Interests - Candel Therapeutics; Context Therapeutics; PrognomIQ; SynDevRx
Consulting or Advisory Role - Candel Therapeutics; Context Therapeutics; OncoCellMDX; PrognomIQ; SynDevRx
Patents, Royalties, Other Intellectual Property - Chromosome Copy Number Gain as a Biomarker of Urothelial Carcinoma Lethality; Composition and Methods for Screening and Diagnosis of Prostate Cancer; Drug Combinations to Treat Cancer; Method for Predicting the Risk of Prostate Cancer Morbidity and Mortality; Methods and Kits for Determining Sensitivity to Cancer Treatment; Methods for Predicting Likelihood of Responding to Treatment; Predicting and Treating Prostate Cancer; Somatic ERCC2 Mutations Correlate with Cisplatin sensitivity in muscle-invasive Urothelial Carcinoma (Patent)
Other Relationship - Bayer (I)
 
Lorelei Mucci
Employment - Convergent Therapeutics (I)
Leadership - Context Therapeutics (I); Essa (I)
Stock and Other Ownership Interests - Context Therapeutics (I); Convergent Therapeutics; Essa (I)
Consulting or Advisory Role - Bayer
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
 
Daniel George
Leadership - Capio BioSciences
Stock and Other Ownership Interests - Pfizer
Honoraria - American Association for Cancer Research; Astellas Pharma; AstraZeneca; Aveo; Axess Oncology; Bayer; Eisai; EMD Serono; Exelixis; IDEOlogy Health; Janssen Oncology; Merck; Millennium Medical Publishing; Myovant Sciences; Novartis; OncLive; Pfizer; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Exelixis; Janssen; Merck Sharp & Dohme; Michael J. Hennessy Associates; Myovant Sciences; Novartis; Pfizer; Physicans' Education Resource
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Exelixis (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Expert Testimony - Exelixis
Travel, Accommodations, Expenses - Bayer; Exelixis; Merck; Novartis; Pfizer